LWD
take some responsibility
- Joined
- Apr 4, 2024
- Posts
- 786
- Reputation
- 1,391
PREFACE
As we all know, GLP-1 agonists are highly effective for fat loss. Though, for many, the appetite suppression component is not strong enough at otherwise efficacious doses, therefore the popular amylin receptor agonist Cagrilintide is often paired for peak appetite supression while still reaping the benefits of the GLP's mechanisms, with Retatrutide notably being the best in terms of fat loss outcomes. Cagrilintide is paired so well with a drug like Retatrutide because it targets a different mechanism by mimicking the hormone amylin, which binds to multiple amylin and calcitonin receptors in order to achieve enhanced satiety and slowed gastric emptying.
ELORALINTIDE AND WHY IT'S BETTER
Eloralintide works by specifically targeting AMY1 receptors in the brain and has a 12-fold preference for amylin over calcitonin receptors. This preference minimizes side effects caused by calcitonin receptor activation (one of Cagrilintide's mechanisms) such as nausea and vomiting, while still creating the prolonged feeling of fullness and satiety in the user. As a result, both human and rat trials showed better gastrointestinal tolerability and fewer gastrointestinal side effects compared to Cagrilintide. Furthermore, patients in Phase II clinical trials lost up to 20% of their body weight in 48 weeks at the max dose (9 mg) compared to Cagrilintide's 11.8% body weight reduction in 68 weeks. Eloralintide also has a longer half-life of 14-16 days compared to Cagrilintide's 6-8 days, resulting in a lower dose of Eloralintide being more effective for longer. Phase II trials of Eloralintide also found improvements in glycemic parameters, lipids, and inflammatory markers.
THE FUTURE
Eloralintide appears to provide faster, more robust weight loss with a superior side-effect profile compared to Cagrilintide at a notably lower efficacious dose. As of right now, Eloralintide is in Phase III clinical trials at Eli Lilly, and due to it not being very known, there are not that many grey market suppliers, and the ones that do supply it are extremely overpriced. As previous weight loss drugs, Eloralintide will become cheaper and more widely available as time goes on and make Cagrilintide effectively useless to purchase, similar to what Retatrutide did to Semaglutide and Tirzepatide. I have also heard rumors of a GLP-4, which would be better than Retatrutide, but nothing concrete and more or less just ramblings from members of the community. Would love any information on this if anyone has it.
As we all know, GLP-1 agonists are highly effective for fat loss. Though, for many, the appetite suppression component is not strong enough at otherwise efficacious doses, therefore the popular amylin receptor agonist Cagrilintide is often paired for peak appetite supression while still reaping the benefits of the GLP's mechanisms, with Retatrutide notably being the best in terms of fat loss outcomes. Cagrilintide is paired so well with a drug like Retatrutide because it targets a different mechanism by mimicking the hormone amylin, which binds to multiple amylin and calcitonin receptors in order to achieve enhanced satiety and slowed gastric emptying.
ELORALINTIDE AND WHY IT'S BETTER
Eloralintide works by specifically targeting AMY1 receptors in the brain and has a 12-fold preference for amylin over calcitonin receptors. This preference minimizes side effects caused by calcitonin receptor activation (one of Cagrilintide's mechanisms) such as nausea and vomiting, while still creating the prolonged feeling of fullness and satiety in the user. As a result, both human and rat trials showed better gastrointestinal tolerability and fewer gastrointestinal side effects compared to Cagrilintide. Furthermore, patients in Phase II clinical trials lost up to 20% of their body weight in 48 weeks at the max dose (9 mg) compared to Cagrilintide's 11.8% body weight reduction in 68 weeks. Eloralintide also has a longer half-life of 14-16 days compared to Cagrilintide's 6-8 days, resulting in a lower dose of Eloralintide being more effective for longer. Phase II trials of Eloralintide also found improvements in glycemic parameters, lipids, and inflammatory markers.
THE FUTURE
Eloralintide appears to provide faster, more robust weight loss with a superior side-effect profile compared to Cagrilintide at a notably lower efficacious dose. As of right now, Eloralintide is in Phase III clinical trials at Eli Lilly, and due to it not being very known, there are not that many grey market suppliers, and the ones that do supply it are extremely overpriced. As previous weight loss drugs, Eloralintide will become cheaper and more widely available as time goes on and make Cagrilintide effectively useless to purchase, similar to what Retatrutide did to Semaglutide and Tirzepatide. I have also heard rumors of a GLP-4, which would be better than Retatrutide, but nothing concrete and more or less just ramblings from members of the community. Would love any information on this if anyone has it.
Amylin takes another shot at the obesity prize - PubMed
Amylin takes another shot at the obesity prize
pubmed.ncbi.nlm.nih.gov
A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy - PubMed
Amylin is a thirty-seven amino acid peptide hormone that is secreted from the pancreas with insulin. The peptide hormone amylin activates its receptors in the brain to regulate blood glucose and food appetite. Interestingly, the amylin receptor is the heterodimer of the calcitonin receptor...
pubmed.ncbi.nlm.nih.gov
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity…
Validate User
@Aryan Incel @Alexanderr @chadisbeingmade @Dxniell @rotation @Mandibulary @Nexom @BigBallsLarry @SlayerJonas
Last edited:
